Top Philadelphia, PA Biotech Companies (81)
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Catalyzing Innovation in Pharma with Data-driven Digital Products. The idea of DataZymes germinated with the realization that Pharma Commercial teams had few alternatives to the antiquated and inefficient solutions offered by traditional consulting and technology companies. Already a laggard in analytical maturity, the Pharma industry had been facing challenges to adapt to a Big Data world. We saw that the products offered by technology companies were too rigid and generic to handle novel problems. The custom solutions offered by consulting organizations took too long to deploy and required many services to maintain and improve. We felt the need for a different approach to finding solutions and we knew it would take a different kind of company to build it. That’s why DataZymes. We’re focused on creating the world’s best user experience for working with data, one that empowers people to ask and answer complex questions without requiring them to master querying languages, statistical modeling, or the command line. To achieve this, we are building platforms for integrating, managing, and securing data on top of which we layer applications for fully interactive machine-driven, human-assisted analysis.
Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue.
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 13,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor. From FORTUNE. © 2021 FORTUNE Media IP Limited All rights reserved. Used under license. FORTUNE is a registered trademark of FORTUNE Media IP Limited and is used under license. FORTUNE and FORTUNE Media IP Limited are not affiliated with and do not endorse products or services of, Avantor.
Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.
MOBILion’s technology makes it easy to separate, identify and analyze the most challenging molecules that other instruments fail to detect. Our higher resolution, faster analysis and simpler workflows reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. We make today’s treatment’s safer and more effective, empower tomorrow’s disease prediction and diagnosis, and accelerate the development of new therapies.
INOVIO Pharmaceuticals, Inc. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and protect people from infectious diseases, cancer and HPV-associated diseases. INOVIO’s DNA medicines platform and proprietary smart device can target virtually any DNA sequence. With 15 clinical programs currently in development, INOVIO has the potential to save and protect lives worldwide and power a new decade of DNA medicines. For more information, visit www.inovio.com.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio’s optimized plasmid design and delivery technology have been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, GBM, and prostate cancer, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and COVID-19. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Inovio also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors.
PhenoTech a biotechnology company, engages in the discovery, development, and commercialization of reagents for diagnostic.
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.
From Discovery to Delivery™, Azzur Group provides the life science community with full lifecycle solutions for all their GxP needs. From Azzur Cleanrooms on Demand™ facilities, to labs, training centers, and consulting and advisory offices across the nation, Azzur helps organizations start, scale, and sustain their enterprises. With four decades of service to the industry, we've become a trusted partner to leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain.
Amyndas is a pharmaceutical company
Context Therapeutics is a clinical-stage biopharmaceutical company.
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Braskem America is an indirect wholly owned subsidiary of Braskem S.A. headquartered in Philadelphia. The company is the leading producer of polypropylene in the United States, with six production plants located in Texas, Pennsylvania and West Virginia, an Innovation and Technology Center in Pittsburgh, and an R&D operation in Boston focused on leveraging groundbreaking developments in biotechnology and advanced materials.
Exegenesis Bio is a clinical-stage global cell and gene therapy company that operates in Philadelphia, Boston, China, and Singapore. Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The company is advancing an early to clinical-stage gene therapy pipeline with three initial focused therapeutic areas: CNS, ophthalmology, and Liver. The company’s vision is to develop and increase access to gene and cell therapies for patients around the world! Founded in 2019 with strong financial backing, Exegenesis Bio has developed a rich pipeline of early to clinical stage programs in eye, CNS and liver-directed genetic diseases. The company is building fully integrated, research, development and manufacturing capabilities to support its programs at commercial scale. Exegenesis Bio has recruited a globally experienced management team with extensive experience in building and scaling biotechnology and gene therapy companies. The company has raised over $120 M since beginning operations in 2019 and is now expanding operations to Philadelphia, Boston and Singapore. Exegenesis Bio expects to dose the first patient with its next generation AAV gene therapy for Type 1 Spinal Muscular Atrophy (SMA) this year. The company plans to file two Global INDs in 2022. Website: https://www.exegenesisbio.com/ Contacts: Company Information: [email protected] Business Development: [email protected] Careers: [email protected]
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Work Your Passion. Live Your Purpose.
